Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SELPLG drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SELPLG ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation and tyrosine sulfation. |
View SELPLG Products |
| Gene Delivery | SELPLG Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based binding assays. |
View SELPLG Products |
| Benchmark Ab | Anti-SELPLG Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View SELPLG Products |
| Validator | SELPLG siRNA Set For target knockdown verification and specificity validation in functional assays. |
View SELPLG Products |
| Related Target A | SELP (P-Selectin) Primary physiological ligand of SELPLG; essential for selectin-blocking and cell adhesion assays. |
View SELP Products |
| Related Target B | SELE (E-Selectin) Secondary endothelial ligand involved in leukocyte rolling and homing cascades. |
View SELE Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Post-Translational Modifications (PTMs) | HEK293 Expressed (Native Glycosylation & Tyrosine Sulfation) to preserve physiological binding affinity to Selectins. |
| Conformation-Specific Screening | Lentivirus for Stable Cell Line development, ensuring native membrane topology for flow cytometry and functional assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Sequence Verified siRNA included for target-specific knockdown validation. |
Live SELPLG/CD162 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SELPLG (PSGL-1) therapeutics is intensifying, with major players shifting focus from traditional anti-inflammatory blockades to immune checkpoint modulation in oncology. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of T-cell exhaustion in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Bristol Myers Squibb, Promontory Therapeutics | Solid Tumors, Advanced Malignancies | Blocking Assay (Need sequence-verified, highly sulfated HEK293-expressed SELPLG ECD-Fc) |
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Inflammatory Diseases, Psoriasis | High-Throughput Selectin-Binding Inhibition (Need high-purity SELP/SELE/SELL proteins) |
| Cell Therapies / Bispecifics | Next-Gen Immunotherapy Developers | Hematologic Malignancies, Autoimmune | Target Validation & Specificity (Need Lentivirus for stable cell line construction and FACS validation) |